Carlomagno GroupCollaborations

Teresa Carlomagno

• Methodology for drug design
  Sanofi Aventis, Frankfurt, Germany

  C. Griesinger, MPI, Göttingen, Germany
  AstraZeneca, UK and Sweden

• RNP complexes
  R. Pillai, EMBL Grenoble, France 

  B. Reif, FMP, Berlin, Germany

• Proteasome binders

  M. Kalesse, University of Hannover, Germany 


• V-ATPase inhibitors
  D. Menche, Heidelberg University, Germany

  M.Huss, H. Wieczorek, University of Osnabrück, Germany

• Tubulin and proteasome binders
  M. Kalesse, University of Hannover, Germany